| ²é¿´: 329 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
||
| A question of high priority is whether the approved antiangiogenic regimes are optimally used in terms of dosing, duration, and combination therapy. The role of VEGF (receptor) inhibitors in micrometast atic disease in adjuvant settings (e.g.,upon resection of the primary tumor) will require further research given the paucity of available preclinical data and suitable animal models. |
» ²ÂÄãϲ»¶
304Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
362Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
26×ÔÈ»µØÀíѧ303·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
»¯¹¤Çóµ÷¼Á£¡
ÒѾÓÐ15È˻ظ´
284Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó£¬³õÊÔ329£¬Çó»·¾³¿ÆÑ§Ó빤³Ìµ÷¼Á£¡
ÒѾÓÐ5È˻ظ´
327Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸¼ª´ó»¯Ñ§327Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´

nwsuafliu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 144
- Ó¦Öú: 42 (СѧÉú)
- ½ð±Ò: 2406.9
- É¢½ð: 1449
- ºì»¨: 18
- Ìû×Ó: 1437
- ÔÚÏß: 315.6Сʱ
- ³æºÅ: 136928
- ×¢²á: 2005-12-17
- רҵ: ×÷Îï·Ö×ÓÓýÖÖ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-02-01 22:47:50
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-02-24 12:27:56
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-02-01 22:47:50
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-02-24 12:27:56
| Ò»¸ö¸ß¶ÈÓÅÏÈÎÊÌâÊÇÒѾÅú×¼µÄ¿¹Ñª¹ÜÉú³ÉÖÎÁÆ·½°¸ÊÇ·ñÔÚ¼ÁÁ¿¡¢ÁÆÆÚ¼°ÁªºÏÖÎÁƵȷ½Ã汻ǡµ±²ÉÓ᣼øÓÚȱ·¦¿ÉÓõÄÁÙ´²Êý¾ÝºÍºÏÊʵ͝ÎïÄ£ÐÍ£¬VEGF£¨ÊÜÌ壩ÒÖÖÆ¼ÁÔÚÎ¢×ªÒÆ¼²²¡ÖÐÓÃ×÷¸¨ÖúÒ©£¨ÀýÈ磬Է¢Ö×ÁöÇгý£©Ê±£¬Æä×÷ÓÃÐèÒª½øÒ»²½Ñо¿£¬ |

2Â¥2013-01-31 15:37:08














»Ø¸´´ËÂ¥